Literature DB >> 19546582

Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.

Zhiguo Mao1, Albert C M Ong.   

Abstract

The peroxisome proliferator-activated receptor superfamily (PPARs) comprises a class of nuclear receptors with significant effects in regulating multiple cellular pathways. Much research and clinical interest has surrounded the PPAR-gamma isoform because of its key role in the transcriptional regulation of metabolic pathways and the efficacy of thiazolidinediones, the most clinically used PPAR-gamma agonist, in the management of type 2 diabetes mellitus. In this review, we discuss the pathogenic role of PPAR-gamma in experimental models of kidney disease, clinical trials of thiazolidinediones in diabetic and non-diabetic kidney disease, recent safety concerns surrounding PPAR-gamma agonists and reflect on their potential use in 'orphan' kidney diseases. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19546582     DOI： 10.1159/000224789

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN： 1660-2110


  13 in total

1.  Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity.

Authors:  Zhiguo Mao; Andrew J Streets; Albert C M Ong
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-23

2.  Protective effects of PPARγ agonist in acute nephrotic syndrome.

Authors:  Yiqin Zuo; Hai-Chun Yang; Sebastian A Potthoff; Behzad Najafian; Valentina Kon; Li-Jun Ma; Agnes B Fogo
Journal:  Nephrol Dial Transplant       Date:  2011-05-12       Impact factor: 5.992

3.  Inhibitory effects of peroxisome proliferator-activated receptor γ agonists on collagen IV production in podocytes.

Authors:  Yanjiao Li; Yachen Shen; Min Li; Dongming Su; Weifeng Xu; Xiubin Liang; Rongshan Li
Journal:  Mol Cell Biochem       Date:  2015-04-29       Impact factor: 3.396

Review 4.  Childhood nephrotic syndrome--current and future therapies.

Authors:  Larry A Greenbaum; Rainer Benndorf; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

Review 5.  Lipotoxicity as a trigger factor of renal disease.

Authors:  Adriana Izquierdo-Lahuerta; Cristina Martínez-García; Gema Medina-Gómez
Journal:  J Nephrol       Date:  2016-03-08       Impact factor: 3.902

Review 6.  New treatments for autosomal dominant polycystic kidney disease.

Authors:  Ming-Yang Chang; Albert C M Ong
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

7.  Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone.

Authors:  Zoë L S Brookes; Lewis Ruff; Viralkumar S Upadhyay; Linghong Huang; Sony Prasad; Tirupa Solanky; Surya M Nauli; Albert C M Ong
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-26       Impact factor: 4.733

8.  Rosiglitazone protects against severe hemorrhagic shock-induced organ damage in rats.

Authors:  Fwu-Lin Yang; Yi-Maun Subeq; Chung-Jen Lee; Ru-Ping Lee; Tai-Chu Peng; Horng-Jyh Harn; Bang-Gee Hsu
Journal:  Med Sci Monit       Date:  2011-10

9.  Protective effects of peroxisome proliferator-activated receptor agonists on human podocytes: proposed mechanisms of action.

Authors:  Gianluca Miglio; Arianna Carolina Rosa; Lorenza Rattazzi; Cristina Grange; Giovanni Camussi; Roberto Fantozzi
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 9.473

10.  Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats.

Authors:  Ravi Prakash Rao; Ansima Singh; Arun K Jain; Bhartu Parsharthi Srinivasan
Journal:  J Biomed Res       Date:  2011-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.